ArticleFrontiers in endocrinology2026
Multi-omics profiling identifies an immunometabolic signature associated with endometriosis.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometriosis (EM) is a chronic inflammatory gynaecological disorder affecting approximately 10% of women of reproductive age. Early diagnosis remains challenging because definitive diagnosis still relies on invasive surgical confirmation. This study aimed to characterize systemic immune-metabolic alterations in EM and identify candidate peripheral blood biomarkers through integrated multi-omics profiling. Methods: Peripheral blood samples were collected from 88 participants, including 44 patients with EM T, 22 patients with benign ovarian cysts, and 22 healthy controls. Inflammatory proteomic profiling was performed using the Olink Target 96 Inflammation panel, and untargeted metabolomic analysis was conducted using ultra-high-performance liquid chromatography-high-resolution mass spectrometry (UHPLC-HRMS). Differential expression, pathway enrichment, integrative network analysis, and receiver operating characteristic (ROC) analyses with bootstrap resampling and false discovery rate (FDR) correction were performed. Results: Proteomic analysis revealed significant dysregulation of immune-inflammatory pathways in EM, characterized by enhanced chemokine signaling, cytokine-receptor interactions, and apoptotic activation. Metabolomic profiling identified substantial disturbances in energy metabolism, particularly involving fatty acid β-oxidation, acylcarnitine transport, and amino acid-carbon metabolic reprogramming. Integrated network analysis revealed a candidate immune-metabolic network comprising FGF21, CCL23, CDCP1, and CD8A. Correlation analysis demonstrated that FGF21 was positively associated with lipid oxidation-related metabolites, whereas CCL23 correlated with acylcarnitine species, indicating coordinated immune-metabolic interactions. ROC analyses showed that selected metabolite markers demonstrated moderate discriminatory performance between EM and healthy controls, while combined proteomic-metabolomic models achieved superior diagnostic performance compared with individual markers. Conclusion: Multi-omics profiling revealed coordinated immunometabolic alterations associated with EM, characterized by interconnected inflammatory and metabolic alterations in peripheral blood. These findings provide evidence that systemic immune-metabolic dysregulation is associated with EM and support further evaluation of blood-based biomarker strategies for non-invasive detection. However, these findings are based on a single-center cohort and require validation in independent populations and targeted assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.